Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Versus Bosutinib in CML-CP Previously Treated With 2 or More TKIs
NCT03106779Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Primary completion
- May 2020
- Countries
- 25
01
Overview
A Phase 3 trial of asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Oct 2017; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03106779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106779.